Pharmacologic Treatment of Type 2 Diabetes

Pharmacologic treatment of type 2 diabetes.

s of the 62nd ADA Scientific Sessions, Diabetes 51 [Suppl. 2], 2002). In the former group, insulin sensitivity, acute insulin responses to IV glucose, or glucose levels after OGTT did not change significantly 8 months after the end of the trial, while the latter group showed 26 and 39% falls in insulin sensitivity and insulin response and a 10% increase in glucose levels during the OGTT. Twenty...

Improving oral pharmacologic treatment and management of type 2 diabetes.

Type 2 diabetes and its associated complications impose a substantial burden on those affected by the disease and have a significant economic impact on the national health care system. Recent estimates indicate a substantial increase in diabetes prevalence in the United States in the past decade, with the largest increases occurring in minority populations. Although diet and exercise are import...

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.

Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes

The prevalence of obesity has increased to pandemic levels worldwide and is related to increased risk of morbidity and mortality. Metabolic comorbidities are commonly associated with obesity and include metabolic syndrome, pre-diabetes, and type 2 diabetes. Even if the prevalence of obesity remains stable until 2030, the anticipated numbers of people with diabetes will more than double as a con...

Pharmacogenomic approach in type 2 diabetes treatment

Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...